NICE recommends Alexion’s asfotase alfa across England
Therapy involves patients with paediatric-onset hypophosphatasia – a rare bone disease
Read More
Tag: Alexion
CHMP recommends expanded use for Alexion’s PNH therapy Ultomiris
European drug regulator has recommended Ultomiris for use in children and adolescents with PNH
Read More
AZ scores final clearance for Alexion acquisition in the UK
UK approval of the acquisition comes just a week after the merger scored clearance in the EU
Read More
EC clears AstraZeneca’s acquisition of Alexion
Clearance in the UK is still pending and remains a requirement to complete the proposed deal
Read More
NHS patients with rare blood disorders gain access to Ultomiris
Around 270 people with PNH and 160 people with aHUS will be eligible for the new treatment
Read More
SMC endorses Alexion’s Ultomiris
Committee also accepted Braftovi combination, Ledaga and Zejula for use by NHS Scotland in May decisions
Read More
NICE recommends Alexion’s PNH treatment Ultomiris
C5 complement inhibitor approved to treat PNH in adult patients with haemolysis
Read More
NICE backs restricted use of Ondexxya
Funding backed for reversal of gastrointestinal bleeds but not for intracranial haemorrhage
Read More
EU expands approval of Alexion’s Soliris
At 48 weeks, 98% of patients treated with the drug were relapse free compared to 63% of patients receiving placebo.
Read More
EU approval for Alexion’s PNH drug Ultomiris
The decision allows use of the drug in patients with haemolysis with clinical symptoms indicative of high disease activity
Read More
Alexion to buy Wilson for $855m
Alexion Pharmaceuticals has offered to buy Wilson Therapeutics in a deal worth around $855 million.
Read More
Alexion gears up to file new blood disorder drug
Alexion is gearing up to file its experimental therapy for paroxysmal nocturnal hemoglobinuria (PNH) with regulators on both sides of the Altantic following the success of a late-stage clinical trial.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
